Multicenter phaseⅡstudy of apatinib single or combination therapy in HER2-negative breast cancer involving chest wall metastasis

查看全文 作　　者：Huiping [1]Li;Cuizhi [2]Geng;Hongmei [3]Zhao;Hanfang [1]Jiang;Guohong [1]Song;Jiayang [1]Zhang;Yaxin [1]Liu;Xinyu [1]Gui;Jing [1]Wang;Kun [1]Li;Zhongsheng [4]Tong;Fangyuan [5]Zhao;Junlan [6]Yang;Guoliang [7]Chen;Qianyu [7]Liu;Xu [1]Liang

机构地区：[1]Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing),Department of Breast Oncology,Peking University Cancer Hospital&Institute,Beijing 100142,China;[2]Breast Disease Diagnostic and Therapeutic Center,the Fourth Affiliated Hospital of Hebei Medical University,Shijiazhuang 050019,China;[3]Department of General Surgery,Peking University Third Hospital,Beijing 100191,China;[4]Department of Breast Oncology,Key Laboratory of Breast Cancer Prevention and Therapy,National Clinical Research Center for Cancer,Tianjin Medical University Cancer Institute and Hospital,Tianjin 30060,China;[5]Department of the Public Health Sciences,University of Chicago,Chicago 60637,USA;[6]Department of Medical Oncology,Chinese PLA General Hospital,Beijing 100853,China;[7]Jiangsu Hengrui Medicine Co.Ltd.,Shanghai 200120,China

出　　处：《Chinese Journal of Cancer Research》索引2021年第33卷第2期,共13页

摘　　要：Objective:Breast cancer(BC)with chest wall metastasis(CWM)usually shows rich neovascularization.This trial explored the clinical effect of apatinib on human epidermal growth factor receptor 2(HER2)-negative advanced BC involving CWM.Methods:This trial involved four centers in China and was conducted from September 2016 to March 2020.Patients received apatinib 500 mg/d[either alone or with endocrine therapy if hormone receptor-positive(HR+)]until disease progression or unacceptable toxicity.Progression-free survival(PFS)was the primary endpoint.Results:We evaluated 26 patients for efficacy.The median PFS(mPFS)and median overall survival(mOS)were4.9[range:2.0-28.5;95%confidence interval(95%CI):2.1-8.3]months and 18(range:3-55;95%CI:12.9-23.1)months,respectively.The objective response rate(ORR)was 42.3%(11/26),and the disease-control rate was76.9%(20/26).In the subgroup analysis,HR+patients compared with HR-negative patients had significantly improved mPFS of 7.0(95%CI:2.2-11.8)months vs.2.3(95%CI:1.2-3.4)months,respectively(P=0.001);and mPFS in patients without or with chest wall radiotherapy was 6.4(95%CI:1.6-19.5)months vs.3.0(95%CI:1.3-4.6)months,respectively(P=0.041).In the multivariate analysis,HR+status was the only independent predictive factor for favorable PFS(P=0.014).Conclusions:Apatinib was highly effective for BC patients with CWM,especially when combined with endocrine therapy.PFS improved significantly in patients with HR+status who did not receive chest wall radiotherapy.However,adverse events were serious and should be carefully monitored from the beginning of apatinib treatment. 关键词：Apatinib advanced breast cancer chest wall metastasis HER2-negative

相关文献

参考文献（45）
引证文献（4）
耦合文献（1023）

参考文献(45)

引证文献(4)

耦合文献(1023)

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

Multicenter phaseⅡstudy of apatinib single or combination therapy in HER2-negative breast cancer involving chest wall metastasis

参考文献(45)

引证文献(4)

耦合文献(1023)

用户提示